MPN

A decision to rename myeloproliferative neoplasms led to a plethora of developments in a space where there was once little interest.

A clinical trial recently kicked off, analyzing the combination of imetelstat plus Jakafi for the treatment of myelofibrosis, a type of rare blood cancer.

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement.

Treatment with Ayvakit was associated with promising outcomes in patients with mastocytosis, according to findings from the PIONEER trial.

The FDA has set a date to decide whether or not to approve momelotinib for myelofibrosis, a rare type of blood cancer.

Sierra Oncology noted in a company-issued press release that if momelotinib is approved by the FDA that they anticipate making the drug available to patients with myelofibrosis next year.

It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.

From Tampa Bay Buccaneers quarterback Tom Brady letting children with cancer dye his hair orange to the name of a cancer drug causing controversy at the Scripps National Spelling Bee, here’s what’s happening in the cancer space this week.

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.

Myelofibrosis may cause major impairments to a patient’s quality of life, which is why it is pertinent that patients work with their clinicians to address these side effects.

Watch Dr. Jamile Shammo and Dr. Srdan Vestovsek answer questions about disease approaches during the CURE Educated Patient MPN Summit.

Watch Dr. Srdan Vestovsek, from The University of Texas MD Anderson Cancer Center, discuss novel agents and clinical trials in myelofibrosis, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile Shammo, from Rush University Medical Center, discuss differentiating an essential thrombocythemia diagnosis, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile Shammo, Dr. Angela Fleishman and Kapila Viges answer questions about clinical trials during the CURE Educated Patient MPN Summit.

Watch Kapila Viges, from the MPN Research Foundation, discuss clinical trials, during the CURE Educated Patient MPN Summit.

Watch Dr. Angela Fleishman, from the University of California Irvine, discuss novel agents and clinical trials in polycythemia vera, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile Shammo, Dr. Aaron Gerds and Dr. Bart Scott, answer questions during the diagnoses and treatment panel during the CURE Educated Patient MPN Summit.

Watch Dr. Bart Scott, from Fred Hutchinson Cancer Center, discuss current treatment options, during the CURE Educated Patient MPN Summit.

Watch Dr. Aaron Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss approaches to diagnosing and assessing symptoms, during the CURE Educated Patient MPN Summit.

From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.

Patients with myeloproliferative neoplasms, a group of blood cancers, who plan to conceive should talk with their doctor about their obstetric and medical history and risk of complications, according to an expert.

A patient’s experience with polycythemia vera — a rare blood cancer — led to her becoming an advocate for others to help ease all the nerves and uncertainty that many patients face when they hear they have cancer.

Recently approved, by the Food and Drug Administration, Besremi has demonstrated to be effective and safe for patients with polycythemia vera — adding hope to their treatment regimen.

The Food and Drug Administration’s greenlight of Vonjo marks the first approved therapy to address the needs of patients with cytopenic myelofibrosis, a type of myeloproliferative neoplasm.